Skip to main content
Erschienen in: World Journal of Urology 4/2017

22.07.2016 | Original Article

Analysis of active surveillance uptake for low-risk localized prostate cancer in Canada: a Canadian multi-institutional study

verfasst von: Narhari Timilshina, Veronique Ouellet, Shabbir M. H. Alibhai, Anne-Marie Mes-Masson, Nathalie Delvoye, Darrel Drachenberg, Antonio Finelli, Marie-Paule Jammal, Pierre Karakiewicz, Hélène Lapointe, Jean-Baptiste Lattouf, Kenny Lynch, Jean-Benoît Paradis, Paula Sitarik, Alan So, Fred Saad

Erschienen in: World Journal of Urology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Although the uptake of active surveillance (AS) appears to be increasing in published series, the uptake in most geographic regions remains largely unknown. Our aim was to examine practice patterns around the use of AS in low-risk prostate cancer in Canada. In addition, we examined regional variations in AS uptake, predictors of AS uptake, and persistent use for 12 months.

Methods

This is a retrospective multicentre review of low-risk patients who underwent a prostate biopsy in 2010 in six centres in four provinces (BC, QC, MB and ON). AS was identified based on chart review and required a minimum of 6 months of follow-up after diagnosis without any active treatment.

Results

Of 986 patients, 781 patients (mean age 64 years) were incident cases and over three-quarters (77.3 %) chose AS at diagnosis. There were significant differences in uptake of AS by centre (range 65.0–98.0 %, p ≤ 0.05). Key multivariate predictors of pursuing AS included older age (OR 1.34, p = 0.044), centre (p = 0.021), lower number of cores (OR 1.09, p = 0.025), lower number of positive biopsy cores (OR 0.52, p < 0.001), and lower percent core involvement (OR 0.84, p < 0.001). In total, 516 (85.4 %) men remained on AS over 12 months. Maintenance with AS over 12 months differed by centre, ranging from 64.1 to 93.9 % (p = 0.001). Predictors of maintenance with AS over 12 months included older age, centre, and lower number of positive cores.

Conclusions

Active surveillance is widely practiced across Canada, but important regional differences were observed. Further analyses are required to understand the root causes of differences and to determine whether AS uptake is changing over time.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Bray F, Lorten-Tieulent J, Ferlay J et al (2010) Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eng J Cancer 46(17):3040–3052CrossRef Bray F, Lorten-Tieulent J, Ferlay J et al (2010) Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eng J Cancer 46(17):3040–3052CrossRef
3.
Zurück zum Zitat Klotz L, Zhang L, Lam A et al (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131CrossRefPubMed Klotz L, Zhang L, Lam A et al (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131CrossRefPubMed
4.
Zurück zum Zitat Cooperberg MR, Broering JM, Kantoff PW et al (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178:S14–S19CrossRefPubMedPubMedCentral Cooperberg MR, Broering JM, Kantoff PW et al (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178:S14–S19CrossRefPubMedPubMedCentral
5.
6.
Zurück zum Zitat Dall’Era MA, Albertsen PC, Bangma C et al (2012) Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 63:976–983CrossRef Dall’Era MA, Albertsen PC, Bangma C et al (2012) Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 63:976–983CrossRef
7.
Zurück zum Zitat Dragomir A, Cury FL, Aprikian AG (2014) Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison. CMAJ Open 2(2):E60–E68CrossRefPubMedPubMedCentral Dragomir A, Cury FL, Aprikian AG (2014) Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison. CMAJ Open 2(2):E60–E68CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Alibhai SMH, Breunis H, Timilshina N et al (2010) Impact of androgen-deprivation therapy on physical function and quality of life in men with non-metastatic prostate cancer. J Clin Oncol 28:5038–5045CrossRefPubMed Alibhai SMH, Breunis H, Timilshina N et al (2010) Impact of androgen-deprivation therapy on physical function and quality of life in men with non-metastatic prostate cancer. J Clin Oncol 28:5038–5045CrossRefPubMed
10.
Zurück zum Zitat Abdollah F, Sun M, Schmitges J et al (2012) Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics. J Urol 188(1):73–83CrossRefPubMed Abdollah F, Sun M, Schmitges J et al (2012) Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics. J Urol 188(1):73–83CrossRefPubMed
11.
Zurück zum Zitat Klotz L, Vesprini D, Sethukavalan P et al (2015) Long term follow up of large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33(3):272–277CrossRefPubMed Klotz L, Vesprini D, Sethukavalan P et al (2015) Long term follow up of large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33(3):272–277CrossRefPubMed
12.
Zurück zum Zitat Matthew Andrews J, Ashfield JE, Morese M et al (2014) Five-year follow up of active surveillance for prostate cancer: a Canadian community-based urological experience. Can Urol Assoc J 8(11–12):E768–E774CrossRefPubMedPubMedCentral Matthew Andrews J, Ashfield JE, Morese M et al (2014) Five-year follow up of active surveillance for prostate cancer: a Canadian community-based urological experience. Can Urol Assoc J 8(11–12):E768–E774CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Stattin P, Holmberg E, Johansson JE et al (2010) Outcomes in localized prostate cancer: National Prostate Cancer registers of Sweden follow-up study. J Natl Cancer Inst 102(13):950–958CrossRefPubMedPubMedCentral Stattin P, Holmberg E, Johansson JE et al (2010) Outcomes in localized prostate cancer: National Prostate Cancer registers of Sweden follow-up study. J Natl Cancer Inst 102(13):950–958CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Filson CP, Chroeck FR, Ye Z et al (2014) Variation in use of active surveillance among men undergoing expectant management for early state prostate cancer. J Urol 192:75–80CrossRefPubMed Filson CP, Chroeck FR, Ye Z et al (2014) Variation in use of active surveillance among men undergoing expectant management for early state prostate cancer. J Urol 192:75–80CrossRefPubMed
15.
Zurück zum Zitat Mohler J, Armstrong A, Bahnson R et al (2012) Prostate cancer, version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 10:1081–1087PubMed Mohler J, Armstrong A, Bahnson R et al (2012) Prostate cancer, version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 10:1081–1087PubMed
16.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373–383CrossRefPubMed Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373–383CrossRefPubMed
17.
18.
Zurück zum Zitat Maurice MJ, Abouassaly R, Kim SP, Zhu H (2015) Contemporary nationwide patterns of active surveillance use for prostate cancer. JAMA Intern Med 175(9):1569–1571CrossRefPubMed Maurice MJ, Abouassaly R, Kim SP, Zhu H (2015) Contemporary nationwide patterns of active surveillance use for prostate cancer. JAMA Intern Med 175(9):1569–1571CrossRefPubMed
19.
Zurück zum Zitat Loeb S, Folkvaljon, Makarov DV et al (2015) Five-year nationwide follow-up study of active surveillance for prostate cancer. Eur Urol 67(2):238CrossRef Loeb S, Folkvaljon, Makarov DV et al (2015) Five-year nationwide follow-up study of active surveillance for prostate cancer. Eur Urol 67(2):238CrossRef
20.
Zurück zum Zitat Womble PR, Montie JE, Ye Z et al (2015) Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur Urol 67(1):44–50CrossRefPubMed Womble PR, Montie JE, Ye Z et al (2015) Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur Urol 67(1):44–50CrossRefPubMed
21.
Zurück zum Zitat Loeb S, Berglund A, Stattin P (2013) Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J Urol 190(5):1742–1749CrossRefPubMed Loeb S, Berglund A, Stattin P (2013) Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J Urol 190(5):1742–1749CrossRefPubMed
22.
Zurück zum Zitat Cooperberg MR, Carroll PR, Klotz L (2011) Active surveillance for prostate cancer: progress and promise. J Clin Oncol 29(27):3669–3676CrossRefPubMed Cooperberg MR, Carroll PR, Klotz L (2011) Active surveillance for prostate cancer: progress and promise. J Clin Oncol 29(27):3669–3676CrossRefPubMed
23.
Zurück zum Zitat Weerakoon M, Papa N, Lawrentschuk N et al (2015) The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian prostate cancer registry. BJU Int 115(suppl 5):50–56CrossRefPubMed Weerakoon M, Papa N, Lawrentschuk N et al (2015) The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian prostate cancer registry. BJU Int 115(suppl 5):50–56CrossRefPubMed
24.
Zurück zum Zitat Graham J, Kirkbride P, Cann K, Hasler E, Prettyjohns M (2014) Prostate cancer: summary of updated NICE guidance. BMJ 348:f7524CrossRefPubMed Graham J, Kirkbride P, Cann K, Hasler E, Prettyjohns M (2014) Prostate cancer: summary of updated NICE guidance. BMJ 348:f7524CrossRefPubMed
Metadaten
Titel
Analysis of active surveillance uptake for low-risk localized prostate cancer in Canada: a Canadian multi-institutional study
verfasst von
Narhari Timilshina
Veronique Ouellet
Shabbir M. H. Alibhai
Anne-Marie Mes-Masson
Nathalie Delvoye
Darrel Drachenberg
Antonio Finelli
Marie-Paule Jammal
Pierre Karakiewicz
Hélène Lapointe
Jean-Baptiste Lattouf
Kenny Lynch
Jean-Benoît Paradis
Paula Sitarik
Alan So
Fred Saad
Publikationsdatum
22.07.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 4/2017
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-016-1897-0

Weitere Artikel der Ausgabe 4/2017

World Journal of Urology 4/2017 Zur Ausgabe

Neu im Fachgebiet Urologie

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.